• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care
Prostate Cancer : Episode 3

Episode 3 - Radium-223 for the Treatment of CRPC

Video

In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer (CRPC).

Dr Crawford cites the ALSYMPCA clinical trial and explains how the trial tested radium-223 and found that the drug demonstrated several benefits to patients with CRPC. Benefits included increased survival rates, decreased instances of overall pain, and lower numbers of symptomatic skeletal events and fractures, as well as lessened the need for treatment with surgery or radiation.


Related Videos
Most employees are unprepared to shop for coverage on their own, underscoring the need for stronger decision tools and consumer protections.
Experts warn that ICHRAs could either stabilize or destabilize the individual market, depending on which workers employers shift into these plans.
Aleata Postell, SVP of pharmacy business development, CenterWell Pharmacy
Where patients live may shape outcomes in hypertrophic cardiomyopathy, with SDOH linked to higher risks of heart failure and arrhythmias.
Dr Eric Yang
Adam Brufsky, MD, PhD, University of Pittsburgh
Dr Marco Del Riccio
Dr Steven Manobianco
Dr Amrita Basu
Danielle Roman, PharmD, BCOP, Allgheny Health Network
Related Content
© 2026 MJH Life Sciences
AJMC®
All rights reserved.